Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.97 USD
+0.05 (0.42%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.96 -0.01 (-0.08%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Roivant Sciences Ltd falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 125 | 61 | 55 | 24 | NA |
Cost Of Goods | 16 | 13 | 9 | 2 | NA |
Gross Profit | 109 | 48 | 46 | 22 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | -4,133 | 1,223 | 1,398 | 1,093 | 0 |
Income After Depreciation & Amortization | 4,242 | -1,175 | -1,352 | -1,071 | 0 |
Non-Operating Income | 46 | -22 | 428 | 172 | NA |
Interest Expense | 35 | 28 | 0 | 0 | NA |
Pretax Income | 4,253 | -1,225 | -924 | -899 | NA |
Income Taxes | 22 | 5 | 0 | 2 | NA |
Minority Interest | -118 | -106 | -79 | -91 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | 4,231 | -1,230 | -924 | -900 | NA |
Extras & Discontinued Operations | 0 | 115 | 0 | 0 | NA |
Net Income (GAAP) | 4,349 | -1,009 | -845 | -809 | NA |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 4,264 | -1,156 | -1,352 | -1,071 | 0 |
Depreciation & Amortization (Cash Flow) | 22 | 19 | 0 | 0 | NA |
Income After Depreciation & Amortization | 4,242 | -1,175 | -1,352 | -1,071 | 0 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 831.05 | 712.79 | 669.75 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.15 | -1.58 | -1.26 | NA | NA |
Diluted Net EPS (GAAP) | 5.23 | -1.42 | -1.26 | NA | NA |
Fiscal Year end for Roivant Sciences Ltd falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 55.13 | 28.93 | 37.14 | 37.10 | 21.62 |
Cost Of Goods | 3.98 | 4.41 | 3.67 | 3.27 | 4.21 |
Gross Profit | 51.15 | 24.52 | 33.47 | 33.84 | 17.41 |
SG&A, R&D, and Dept/Amort Expenses | 171.34 | 290.52 | -5,027.41 | 310.29 | 293.82 |
Income After SG&A, R&D, and Dept/Amort Expenses | -120.19 | -266.00 | 5,060.88 | -276.45 | -276.41 |
Non-Operating Income | 203.73 | 81.72 | 46.90 | -41.66 | -40.77 |
Interest Expense | 13.40 | 7.18 | 9.44 | 9.25 | 8.91 |
Pretax Income | 70.15 | -191.45 | 5,098.34 | -327.36 | -326.09 |
Income Taxes | 12.66 | -8.96 | 25.67 | 3.76 | 1.75 |
Minority Interest | -37.81 | -31.38 | -23.52 | -26.79 | -36.03 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 57.49 | -182.50 | 5,072.67 | -331.12 | -327.85 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 95.30 | -151.11 | 5,096.18 | -304.33 | -291.82 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 781.63 | 802.86 | 844.46 | 770.23 | 759.27 |
Diluted EPS Before Non-Recurring Items | -0.24 | -0.28 | -0.26 | -0.33 | -0.38 |
Diluted Net EPS (GAAP) | 0.12 | -0.02 | 6.03 | -0.40 | -0.38 |